No headlines found.
PRNewswire (Thu, 7-May 6:38 AM ET)
Generate Biomedicines Inc is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company's single operating segment is engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its product candidates include: GB-0895, GB-4362, and GB-5267. Through the company's Generate Platform, it can generate medicines on demand across multiple therapeutic modalities with unprecedented speed representing a fundamental shift in drug discovery.
Generate Biomedicines trades on the NASDAQ stock market under the symbol GENB.
As of May 27, 2026, GENB stock price declined to $13.08 with 553,847 million shares trading.
GENB has a beta of 1.02, meaning it tends to be more sensitive to market movements. GENB has a correlation of 0.04 to the broad based SPY ETF.
GENB has a market cap of $1.67 billion. This is considered a Small Cap stock.
Last quarter Generate Biomedicines reported $7 million in Revenue and -$1.07 earnings per share. This beat revenue expectation by $1 million and missed earnings estimates by -$.59.
The top ETF exchange traded funds that GENB belongs to (by Net Assets): ARKG, VTI, ONEQ, VXF, GNMX.
GENB support price is $12.53 and resistance is $14.15 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that GENB shares will trade within this expected range on the day.
